Articles by Ray Dogum

  1. 2026 Nucleate Boston Activator Cohort Interview: Michael Cronce — Omni Therapeutics 6/9/2026

    Omni Therapeutics is developing first-in-class nucleotides from a novel immune metabolite, using Nucleate support to advance colorectal cancer programs.

  2. A New De Novo Protein Design Platform For GPCR Drug Discovery 6/9/2026

    Skape Bio and UW created an AI-driven platform to design miniproteins that modulate GPCRs in living cells, opening new paths for biologic drug discovery.

  3. Advancing Spatial Multiomics for Discovery: From Promise to Practice 6/5/2026

    Spatial multiomics offers extraordinary biological insight, but high costs, tissue bottlenecks, and unclear clinical relevance still limit its reach.

  4. Discovery Dialogues: Winston Haynes, VP, Computational Sciences and Engineering, LabGenius Tx 6/5/2026

    DDO interviewed Winston Haynes, VP, computational sciences and engineering, LabGenius Tx, on their T-cell engagers platform, including its lead candidate LGTX-101, a Nectin-4 CD3 molecule showing strong preclinical efficacy.

  5. Discovery Dialogues: Stef van Grieken, CEO, Cradle Bio 6/5/2026

    DDO caught up with Stef van Grieken, CEO of Cradle Bio, which uses AI to speed protein design, putting tools in scientists’ hands. Gains in lead optimization are clear, but safety CMC and tough targets remain key challenges.

  6. Discovery Dialogues: Helen Bright, Ph.D., CSO of Centauri Tx 6/4/2026

    At PEGS Boston, Helen Bright, PhD explained how Centauri’s CTX187 harnesses innate immunity to fight resistant gram-negative infections and support better outcomes.

  7. Fostering Entrepreneurial Mentorship And Education: A Peek Into Nucleate Boston Activator 2026 Cohort 6/3/2026

    Nucleate Boston’s 2026 Activator shows how mentorship, structure, and community can help promising young scientists become credible biotech founders.

  8. Unfolding Protein & Antibody Discovery At PEGS 2026 5/19/2026

    Our editorial team covers the 2026 Protein & Antibody Engineering Summit (PEGS) in Boston -- A working map of where biologics R&D is headed.

  9. From Urine-Derived To Recombinant Precision: KLK1 Reimagined For Preeclampsia 5/8/2026

    DiaMedica is testing a synthetic, first-in-class recombinant human kallikrein‑1 (rhKLK1) biologic in Phase 2 clinical trials to treat preeclampsia, which remains one of the most dangerous complications of pregnancy.

  10. Next‑Generation Omics: Latest Insights From A Growing Field 4/8/2026

    Experts share their latest discovery and translational research using multi-omics technologies at the NextGen Omics Spatial & Data conference in Boston.